Gilead Sciences (NASDAQ:GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and Descovy. The lawsuit stemmed from research Gilead (NASDAQ:GILD) conducted with the U.

"The CDC must be investigated for its misuse of PEPFAR funds," said Sen. Jim Risch (R-Idaho), following a report that funds for the global AIDS-fighting program were used for abortions during the Biden administration. ( Politico)

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills.

Scientists discovered that repetitive HIV vaccinations can lead the body to produce antibodies targeting the immune complexes already bound to the virus — knowledge that could lead to better vaccines.

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection.

A major U.S. HIV/AIDS relief program is facing potential blowback amid reports that the program was used to fund abortions in southeast Africa.

In its litigation, the government alleged Gilead (GILD) had overstated its contribution in developing a preventive HIV regimen with the drug, ignored the CDC's contributions and failed to license ...

Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund explains the biggest HIV issues anticipated this year.

HIV infections (human immunodeficiency virus infections) include the spectrum of infections caused by the virus HIV that range from asymptomatic seropositivity to acquired immunodeficiency ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP).